The 2020 Story

The awards ceremony at the 2020 World ADC Digital event was unique and first of its kind, delivered through video. However, everyone’s involvement, collaboration and energy made the virtual experience just as enjoyable!  

The 7th annual World ADC Awards showcased the innovation, leadership and devotion shown by the best companies, teams and individuals in the industry.

Across 9 categories the Awards recognized the extraordinary endeavors, teamwork and commercial acumen that has propelled the field to the forefront of cancer research today.

The finalists and winners were shortlisted from over 1000 votes cast and scientific proposals from each submission were evaluated by our Judging panel.

This year, given the exciting developments in the field, we are looking forward to the 8th Annual World ADC Awards ceremony taking place virtually on Tuesday, October 12.

The 2021 Shortlist:

Best ADC Platform Technology

Ajinomoto Biopharma Services

Araris Biotech AG

Legochem Bio (Scaffold Based

Synaffix (GlycoConnect™ & Hy

Sutro Biopharma (cell-free exp

Best New Drug Developer




Bolt Biotherapeutics

Silverback Therapeutics


Most Promising Clinical Candidate

Camidanlumab Tesirine (ADCT-301)

Trastuzumab duocarmazine (SYD985)    


CX2029 (CytomX, CD71 PDC)

patritumab deruxtecan (HER3-DXd; formerly U3-1402


Best Contract Manufacturing (CMO) Provider

BSP Pharmaceuticals

Millipore Sigma

Wuxi Biologics

Ajinomoto Biopharma Services



Best Contract Research (CRO) Provider

NJ Bio

Charles River






The 2020 Winners Are:

Best ADC Platform Technology

Synaffix – Winner

Legochem Bio – Runner Up

Best New Drug Developer

Sutro Biopharma – Winner
Mersana Therapeutics – Runner Up


Most Promising Clinical Candidate

DS-1062 (Daiichi Sankyo) – Winner
Loncastuximab Tesirine (ADC Therapeutics) – Runner Up


Best Contract Manufacturing (CMO) Provider

Piramal – Winner
BSP Pharmaceuticals – Runner Up


Best Contract Research (CRO) Provider

Abzena – Winner

NJ Biopharmaceuticals  – Runner Up


Best Pre-Clinical Publication


Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation.

Czechowicz A, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Pang WW, Mansour MK, Tate TA, Chan YY, Walck E, Wernig G, Shizuru JA, Winau F, Scadden DT, Rossi DJ.Nat Commun. 2019 Feb 6;10(1):617. doi: 10.1038/s41467-018-08201-x.


AJICAP: Affinity Peptide Mediated Regiodivergent Functionalization of Native Antibodies.

Yamada K, Shikida N, Shimbo K, Ito Y, Khedri Z, Matsuda Y, Mendelsohn BA.Angew Chem Int Ed Engl. 2019 Apr 16;58(17):5592-5597. doi: 10.1002/anie.201814215. Epub 2019 Mar 29.


Best Clinical Publication


Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators.N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017.


Individual Input to the Field 2019

Aldo Braca (BSP Pharmaceuticals)


Long Standing Contribution to the Field

Rakesh Dixit